NY-ESTÉE-LAUDER
14.9.2022 22:31:34 CEST | Business Wire | Press release
Today, Executive Chairman William P. Lauder and President and Chief Executive Officer Fabrizio Freda of The Estée Lauder Companies Inc. (NYSE:EL) (“ELC”) announced an organizational evolution across its brand portfolio to strategically position the company for long-term, sustainable growth in a fast-paced evolving global landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005700/en/
Jane Hertzmark Hudis, Executive Group President, The Estée Lauder Companies (Photo: Business Wire)
Effective September 1, 2022, the company’s brand portfolio evolved into two brand clusters led by Jane Hertzmark Hudis, Executive Group President, and Stéphane de La Faverie, who has been promoted to Executive Group President. This new brand leadership structure is designed to ensure continued portfolio-wide alignment, enabling the business to focus on the greatest areas of opportunity. Jane and Stéphane will continue to report directly to Fabrizio Freda.
“This evolution further positions The Estée Lauder Companies’ brands to win with consumers in a complex and continuously changing beauty landscape, while elevating our internal talent bench and organizational planning to position us well to deliver on the company’s long-term strategy with agility,” said Fabrizio Freda. “The strength of our portfolio reflects the strength of our leadership team, and this evolution leverages the track record and high potential of each leader to take our business to even greater heights in the future.”
Building upon their enterprise-wide leadership responsibilities, Jane and Stéphane, in partnership with the Brand Presidents, will oversee their brands’ businesses, equity and innovation, continuing to work in close alignment with all internal functions and regions. Additionally, they will work closely with brand and value chain leaders to drive the strategy and growth plans for the company’s product categories and key subcategories.
“We have been and will continue to be a brand-led company. This exciting update to the organization will further enable our brands’ industry leadership,” said William P. Lauder. “Leveraging ELC’s internal talent pipeline globally underscores our commitment to create new professional development and career advancement opportunities for the next generation of leaders across our organization.”
This organizational evolution aligns with ELC’s forward-looking corporate strategy and Compass to accelerate the company’s ability to deliver now while simultaneously preparing for the future. The company’s top brand leaders are organizationally aligned in a management structure designed to promote cross-brand synergies and advance development at multiple levels of the organization. In line with the company’s internal talent vision, this announcement also includes the appointment of several leaders to elevated brand roles within the clusters of Jane and Stéphane.
Executive Group President Jane Hertzmark Hudis will continue leading one of the company’s brand clusters, with a portfolio of brands that includes: La Mer and Bobbi Brown; TOM FORD BEAUTY; M·A·C; Clinique and Origins; Aveda; Bumble and bumble; and Dr.Jart+. Jane will also continue her enterprise-wide executive leadership of skin care and hair care, which are important growth-driving categories for our company. All the current brand leaders will remain the same, with the exception of Sandra Main taking direct responsibility of La Mer. In addition, Jane will continue as an executive sponsor for key strategic enterprise-wide priorities, including initiatives focused on marketing excellence and winning with Chinese consumers.
As one of the most accomplished, visionary executives in prestige and luxury beauty, Jane has a proven track record of leading, building, and transforming global brands to achieve outstanding broad-based growth. Jane will leverage her tenured expertise, including her vast knowledge of China, luxury beauty, and consumer-centric local relevance, to further enable her brand portfolio to win across categories, regions, and channels.
Jane is a passionate advocate of leadership development, mentorship, and women’s advancement. In addition to her enterprise-wide responsibilities at the company, Jane co-founded The Estée Lauder Companies’ Women’s Leadership Network (“WLN”) in 2017 to inspire and engage women across the organization, helping them become exceptional leaders and mentors. Under Jane’s co-executive sponsorship, WLN has become the company’s largest employee resource group with a presence in every region.
As Executive Group President, Stéphane de La Faverie will continue to lead one of the company’s brand clusters including Estée Lauder and AERIN Beauty; Jo Malone London; Le Labo; KILIAN PARIS, Editions de Parfums Frederic Malle, Darphin Paris and LAB Series; and DECIEM (The Ordinary, NIOD, and Avestan). Additionally, Stéphane will add ELC’s California-based brands to his portfolio – Too Faced; Smashbox and GLAMGLOW – expanding his category leadership to now include makeup, in addition to fragrance and subcategories of home, bath and body, and men’s skin care and grooming. With the exception of Estée Lauder, all the leaders of the brands now in Stéphane’s portfolio remain the same. Stéphane will also continue to drive integrated planning and end-to-end business operations enterprise-wide.
Stéphane’s promotion to Executive Group President reflects his outstanding track record of building successful global brands and his deep expertise across categories and channels, helping build fragrance as a powerful engine of growth for the company, and leading the Estée Lauder brand to be one of the world’s most beloved prestige beauty brands.
Stéphane’s strength as an inclusive and empathic leader, and his ability to balance emotional inspiration, authenticity and strategic insights to drive long-term, sustainable growth, have helped him successfully build his portfolio of brands and nurture a winning leadership team.
Additional Brand Leadership Updates
- Justin Boxford has been appointed Global Brand President, Estée Lauder. He will report to Stéphane. A separate announcement on Justin’s appointment will be shared in the coming days.
- Sandra Main, Global Brand President, La Mer and Bobbi Brown, will assume direct leadership of La Mer and will oversee Bobbi Brown until a new leader is named. Sandra will continue reporting to Jane.
- Michelle Freyre has been promoted to Global Brand President, Clinique and Origins, expanding her brand oversight. Michelle will report to Jane.
- Amber Garrison, who assumed the role of Global Brand President, Origins in July 2022, will continue as a member of Jane’s leadership team and report to Michelle Freyre.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, LAB Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-L
ELC-C
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005700/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
